Ali Farooqui
Psychiatry · Louisville, KYNPI 1598076705
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $339,848 of the $392,530 with a category attached, or 86.6%. AbbVie accounts for 72.6% of it on its own, with 26 other manufacturers making up the rest. 2025 is the largest year on record at $205,523, more than ten times the $596 reported in 2019. Among psychiatry clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 739 payments — averaging $531.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$285K
- Braeburn Inc.$40K
- Vanda Pharmaceuticals Inc.$38K
- Bioxcel Therapeutics, Inc.$20K
- Brainsway USA Inc$2K
- Alkermes, Inc.$1K
- plus $6K from 21 others
What the payments were for
- Speaking & faculty fees$339,84887%
- Travel & lodging$33,0728%
- Food & beverage$19,4805%
- Education$1300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 428 | $284,873 |
| Braeburn Inc. | 65 | $39,820 |
| Vanda Pharmaceuticals Inc. | 67 | $37,904 |
| Bioxcel Therapeutics, Inc. | 46 | $20,247 |
| Brainsway USA Inc | 1 | $2,208 |
| Alkermes, Inc. | 22 | $1,055 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 15 | $718 |
| Neuronetics, Inc. | 7 | $661 |
| Teva Pharmaceuticals USA, Inc. | 9 | $624 |
| Otsuka America Pharmaceutical, Inc. | 12 | $555 |
| Johnson & Johnson | 9 | $512 |
| Abbott | 12 | $429 |
| Idorsia Pharmaceuticals US Inc | 6 | $410 |
| Axsome Therapeutics, Inc. | 10 | $395 |
| Neurocrine Biosciences, Inc. | 4 | $362 |
| E.r. Squibb & Sons, L.L.C. | 4 | $311 |
| Sage Therapeutics, LLC | 3 | $218 |
| Tris Pharma Inc | 4 | $200 |
| Davol Inc. | 1 | $196 |
| Livanova USA, Inc. | 2 | $168 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $129 |
| Biogen | 2 | $123 |
| Novo Nordisk | 2 | $118 |
| Acadia Pharmaceuticals Inc | 1 | $114 |
| Boehringer Ingelheim | 1 | $85 |
| Pfizer | 3 | $79 |
| Bausch Health US, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$280,345
- BRIXADI$38,906
- Fanapt$36,802
- IGALMI$19,767
- Brainsway Deep TMS$2,208
- LYBALVI$1,371
- ARISTADA$900
- CAPLYTA$323
- NEUROSTAR TMS THERAPY SYSTEM$291
- NEUROSTAR TMS THERAPY$264
- SPRAVATO$257
- INGREZZA$253
- REXULTI$229
- ARISTADA INITIO$225
- ABILIFY MAINTENA$211
- Phasix Mesh$196
- SUPERA$173
- VNS Therapy Symmetry Model 8103 Generator$145
- Quillichew ER$125
- Dyanavel XR$125
How this compares
$392,530 in reported general payments places this provider in the 95th percentile of 348 psychiatry providers in Kentucky.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 12 | $18,081 |
| Duloxetine Hcl | 15 | $372 |
| Clonazepam | 15 | $324 |
| Bupropion XlBupropion Hcl | 20 | $272 |
| Mirtazapine | 19 | $205 |
| Zolpidem Tartrate | 11 | $102 |
| Lorazepam | 11 | $44 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $284,873 | $18,08112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 348 psychiatry providers in Kentucky.
Other psychiatry in Louisville
- Rifaat El-MallakhLouisville$1.6M
- Robert StewartLouisville$651K
- Stephanie HallLouisville$106K
- Kelly ClarkLouisville$14K
- Michael HarrisLouisville$13K
- Yelena VaninaLouisville$12K
- Mohamed KhodeirLouisville$9K
- Kevin BaysLouisville$9K
- Terry HaganLouisville$8K
- Ronald McGavicLouisville$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.